

CS/NSE&BSE/LOSC/2022-23 June 16, 2022

To The General Manager Department of Corporate Services BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001

Scrip Code: 543064

To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Intimation regarding Loss of Share Certificate(s) under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. A copy of request letter received from Shareholder is enclosed herewith.

Name of the	Folio No.	No. of	Certificate	Distinctive Nos.		date of
Holder		Shares	No.(s)	From	То	receipt of
						information
UMA DEWAN / SATISH KUMAR DEWAN	SPC0164028	1000	164028	126851048	126852047	14/06/2022
		1000	276849	254129674	254130673	14/00/2022

This is for your information and record.

Thanking you, Yours faithfully, For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao Company Secretary Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5 Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN:L24299TG2018PLC128171 Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com

Folio No PSPC0164028

Satish Dewan <skud1316@gmail.com>

Tue 14/06/2022 21:28

To: Investorservices <investorservices@suvenpharm.com>

2 attachments (3 MB)
20220614173343647.pdf; 20220614173534878.pdf;

CAUTION: This email originated from outside of Suven Pharmaceuticals Limited. Do not click links or open attachments unless you recognize the sender and know the content is safe. Please also read the sender email address carefully.

Respected Sirs

Mr. K. Hanumantha Rao, Company Secretary, **Suven Pharmaceuticals Limited.,** 8-2-334, SDE Serene Chambers, ,3rd Floor, Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana - 500034

Subject: 1. Dematerialise Shares Of Suven Pharmaceuticals Limited

- 2. Change Of Address and
- 3. Unclaimed Dividend

Dear Sir,

We have been the loyal shareholders of **Suven Pharmaceuticals Limited** and have neither sold any share of the subject company till date in any exchange nor have dematerialised our shares of **Suven Pharmaceuticals Limited**.

We seem to have misplaced / currently do not hold the physical share certificate of **Suven Pharmaceuticals** Limited.

Though we have received your KYC letter dated 9th May 2022 at our old address i.e., Uma Dewan, 4936, Bara Tooti, Sadar Bazar, Delhi – 110006.

Hence please guide us the process on how to retrieve the share certificate of **Suven Pharmaceuticals Limited** so that the same can be further dematerlised.

At the same time would also like you to kindly update our new address in your records: Uma Dewan

C-24 East Of Kailash Ground Floor New Delhi – 110065

You are requested to kindly delete our old address from your records: Uma Dewan 4936, Bara Tooti, Sadar Bazar, Delhi – 110006 Also I seem to have missed out receiving few old dividend cheques hence request you to have this credited into our Bank account as mentioned below:

Name Of the Bank	: HDFC Bank Ltd.
Name of the account holder	: Uma Dewan and Satish Kumar Dewan
Account No.	: 50100249030291
IFSC	: HDFC0001374
Bank Address	: 89 Hemkunt Chambers, Nehru Place, G2 &3, New Delhi - 110019

Attachments: 1. Aadhar Card2. Pan Card3. Cheque Copy4. Your KYC letter dated 9th May 2022.I am attaching the signed documents.

You are requested to the needful and guide me the way forward.

Thanking You and Yours Sincerely

Uma Dewan

Satish Kumar Dewan

Confidentiality Notice:

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this email is strictly prohibited. If you have received this e-mail transmission in error, please delete the message and any attachments from your Inbox.